Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 2/2016

01-02-2016 | 2015 SSAT Plenary Presentation

Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors

Authors: Irene Y. Zhang, Jing Zhao, Carlos Fernandez-del Castillo, Yvonne Braun, Shadi Razmdjou, Andrew L. Warshaw, Keith D. Lillemoe, Cristina R. Ferrone

Published in: Journal of Gastrointestinal Surgery | Issue 2/2016

Login to get access

Abstract

Introduction

Surgical resection is the only curative treatment for pancreatic neuroendocrine tumors (PNETs), but pancreatic operations carry a significant morbidity. We investigated whether the resection of small, asymptomatic nonfunctioning PNETs is beneficial. Clinicopathologic factors were retrospectively reviewed for all PNET cases from 1998 to 2014.

Methods

Kaplan-Meier survival and multivariable regression analyses were performed. A total of 249 patients had nonfunctioning PNETs with adequate follow-up, of whom 193 were resected and 56 were observed. Median age was 56 years, and 48 % of the patients were female.

Results

Overall, the resected patients had a significantly longer survival (OS) (p = 0.001). However, for the patients with PNETs ≤2.5 cm in size and without metastasis at presentation, tumor size significantly modified the effect of resection on overall survival (p < 0.05). The protective effect of resection increased as tumor size increased. An operation became a significant predictor of overall survival for tumors >1.5 cm (p = 0.050 or less for larger tumors) but was not significant for tumors <1.5 cm (p = 0.317 or more for smaller tumors), controlling for age-adjusted Charlson comorbidity index.

Conclusion

Resection of nonfunctioning PNETs over 1.5 cm is independently and significantly associated with a longer survival. However, the benefit of resection for tumors under 1.5 cm is unclear.
Literature
1.
go back to reference American Cancer Society: Cancer Facts & Figures. Atlanta; 2015. American Cancer Society: Cancer Facts & Figures. Atlanta; 2015.
2.
go back to reference Grimelius L, Hultquist G, Stenkvist B: Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol Anat Histol 1975, 365:275–288.CrossRefPubMed Grimelius L, Hultquist G, Stenkvist B: Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol Anat Histol 1975, 365:275–288.CrossRefPubMed
3.
go back to reference Kimura W, Kuroda A, Morioka Y: Clinical Pathology of Endocrine Tumors of the Pancreas: Analysis of Autopsy Cases. Dig Dis Sci 1991, 36:933–942.CrossRefPubMed Kimura W, Kuroda A, Morioka Y: Clinical Pathology of Endocrine Tumors of the Pancreas: Analysis of Autopsy Cases. Dig Dis Sci 1991, 36:933–942.CrossRefPubMed
4.
go back to reference Marion-Audibert A-M, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle J-A, Partensky C, Scoazec J-Y: Low Microvessel Density Is an Unfavorable Histoprognostic Factor in Pancreatic Endocrine Tumors. Gastroenterology 2003, 125:1094–1104.CrossRefPubMed Marion-Audibert A-M, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle J-A, Partensky C, Scoazec J-Y: Low Microvessel Density Is an Unfavorable Histoprognostic Factor in Pancreatic Endocrine Tumors. Gastroenterology 2003, 125:1094–1104.CrossRefPubMed
5.
go back to reference Couvelard A, O’Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris A, Gatter K, Pezzella F: Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005, 92:94–101.PubMedCentralCrossRefPubMed Couvelard A, O’Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris A, Gatter K, Pezzella F: Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005, 92:94–101.PubMedCentralCrossRefPubMed
6.
go back to reference Pape U-F, Böhmig M, Berndt U, Tiling N, Wiedenmann B, Plöckinger U: Survival and Clinical Outcome of Patients with Neuroendocrine Tumors of the Gastroenteropancreatic Tract in a German Referral Center. Ann N Y Acad Sci 2004, 1014:222–233.CrossRefPubMed Pape U-F, Böhmig M, Berndt U, Tiling N, Wiedenmann B, Plöckinger U: Survival and Clinical Outcome of Patients with Neuroendocrine Tumors of the Gastroenteropancreatic Tract in a German Referral Center. Ann N Y Acad Sci 2004, 1014:222–233.CrossRefPubMed
7.
go back to reference Corleto VD, Panzuto F, Falconi M, Cannizzaro R, Angeletti S, Moretti A, Delle Fave G, Farinati F: Digestive neuroendocrine tumors: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2001, 33:217–221.CrossRefPubMed Corleto VD, Panzuto F, Falconi M, Cannizzaro R, Angeletti S, Moretti A, Delle Fave G, Farinati F: Digestive neuroendocrine tumors: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2001, 33:217–221.CrossRefPubMed
8.
go back to reference Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998, 2:472–482.CrossRefPubMed Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998, 2:472–482.CrossRefPubMed
9.
go back to reference Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey J, Rashid A, Evans DB: One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J Clin Oncol 2008, 26:3063–3072.CrossRefPubMed Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey J, Rashid A, Evans DB: One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J Clin Oncol 2008, 26:3063–3072.CrossRefPubMed
10.
go back to reference Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernandez-del Castillo C: Evolving Patterns in the Detection and Outcomes of Pancreatic Neuroendocrine Neoplasms: the Massachusetts General Hospital Experience from 1977 to 2005. Arch Surg 2007, 142:347–354.PubMedCentralCrossRefPubMed Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernandez-del Castillo C: Evolving Patterns in the Detection and Outcomes of Pancreatic Neuroendocrine Neoplasms: the Massachusetts General Hospital Experience from 1977 to 2005. Arch Surg 2007, 142:347–354.PubMedCentralCrossRefPubMed
11.
go back to reference Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymonifka J, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fernandez-del Castillo C: Implications of Incidentally Discovered, Nonfunctioning Pancreatic Endocrine Tumors: Short-term and Long-term Patient Outcomes. Arch Surg 2011, 146:534–538.PubMedCentralCrossRefPubMed Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymonifka J, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fernandez-del Castillo C: Implications of Incidentally Discovered, Nonfunctioning Pancreatic Endocrine Tumors: Short-term and Long-term Patient Outcomes. Arch Surg 2011, 146:534–538.PubMedCentralCrossRefPubMed
12.
go back to reference Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P, Scarpa A, Falconi M: Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011, 150:75–82.CrossRefPubMed Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P, Scarpa A, Falconi M: Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011, 150:75–82.CrossRefPubMed
13.
go back to reference Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S, Steinmuller T, Oberg K, Scoazec J-Y: Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006, 84:196–211.CrossRefPubMed Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S, Steinmuller T, Oberg K, Scoazec J-Y: Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006, 84:196–211.CrossRefPubMed
14.
go back to reference Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, Klimstra DS, Allen PJ: Determining prognosis in patients with pancreatic endocrine neoplasms: Can the WHO classification system be simplified? J Clin Oncol 2007, 25:5609–5615.CrossRefPubMed Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, Klimstra DS, Allen PJ: Determining prognosis in patients with pancreatic endocrine neoplasms: Can the WHO classification system be simplified? J Clin Oncol 2007, 25:5609–5615.CrossRefPubMed
15.
go back to reference Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF: Pancreatic Neuroendocrine Tumors: the Impact of Surgical Resection on Survival. Cancer 2009:741–751. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF: Pancreatic Neuroendocrine Tumors: the Impact of Surgical Resection on Survival. Cancer 2009:741–751.
16.
go back to reference Sharpe SM, In H, Winchester DJ, Talamonti MS, Baker MS: Surgical Resection Provides an Overall Survival Benefit for Patients with Small Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2014. Sharpe SM, In H, Winchester DJ, Talamonti MS, Baker MS: Surgical Resection Provides an Overall Survival Benefit for Patients with Small Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2014.
17.
go back to reference Kishi Y, Shimada K, Nara S, Esaki M, Hiraoka N, Kosuge T: Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. Ann Surg Oncol 2014, 21:2882–8.CrossRefPubMed Kishi Y, Shimada K, Nara S, Esaki M, Hiraoka N, Kosuge T: Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. Ann Surg Oncol 2014, 21:2882–8.CrossRefPubMed
18.
go back to reference Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino K, Meriden Z, Choti M, Diaz LA, Pawlik TM, Schulick RD, Hruban RH, Edil BH: A single institutions 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems anda new prognostic nomogram. Ann Surg 2014, 259(2):204–212. Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino K, Meriden Z, Choti M, Diaz LA, Pawlik TM, Schulick RD, Hruban RH, Edil BH: A single institutions 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems anda new prognostic nomogram. Ann Surg 2014, 259(2):204–212.
Metadata
Title
Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors
Authors
Irene Y. Zhang
Jing Zhao
Carlos Fernandez-del Castillo
Yvonne Braun
Shadi Razmdjou
Andrew L. Warshaw
Keith D. Lillemoe
Cristina R. Ferrone
Publication date
01-02-2016
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 2/2016
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-015-3043-5

Other articles of this Issue 2/2016

Journal of Gastrointestinal Surgery 2/2016 Go to the issue